Company: NIVFW
Filing Date: 2025-03-07
Form Type: F-1
Source: 0001213900-25-021404
Chunk: 82

Company: NewGenIvf Group Ltd
Filing Date: 2025-03-07
Form: F-1
Chunk 82
---
 also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect its results of operations. In addition, if the resulting business from such a transaction fails to meet NewGenIvf’s expectations, or it fails to successfully integrate such businesses into its own, its business, financial condition and results of operations may be adversely affected or it may be exposed to unknown risks or liabilities. Even when NewGenIvf identifies an appropriate acquisition or investment target, it may not be able to negotiate the terms of the acquisition or investment successfully, obtain financing for the proposed transaction, or integrate the relevant businesses into its existing business and operations. Strategic investments or acquisitions will involve risks commonly encountered in business relationships, including:

| ● | difficulties in assimilating and integrating the operations, personnel,      
 systems, data, technologies, products and services of the acquired business; |

| ● | inability of the acquired technologies, products or businesses to achieve  
 expected levels of revenue, profitability, productivity or other benefits; |

52

| ● | difficulties in retaining, training, motivating and integrating key 
 personnel;                                                          |

| ● | diversion of management’s time and resources from NewGenIvf’s 
 normal daily operations;                                      |

| ● | difficulties in maintaining uniform standards, controls, procedures 
 and policies within the combined organizations;                     |

| ● | difficulties in retaining relationships with customers, employees and 
 suppliers of the acquired business;                                   |

| ● | risks of entering markets in which NewGenIvf have limited or no prior 
 experience;                                                           |

| ● | regulatory risks, including remaining in good standing with existing                                                                
 regulatory bodies or receiving any necessary pre-closing or post-closing approvals, as well as being subject to new regulators with 
 oversight over an acquired business;                                                                                                |

| ● | assumption of contractual obligations that contain terms that are not                                                    
 beneficial to NewGenIvf, require it to license or waive intellectual property rights or increase its risk for liability; |

| ● | failure to further successfully develop the acquired technology; |

| ● | liability for activities of the acquired business before the acquisition,                                                         
 including intellectual property infringement claims, violations of laws, commercial disputes, tax liabilities and other known and 
 unknown liabilities;                                                                                                              |

| ● | potential disruptions to NewGenIvf’s ongoing businesses; and |

| ● | unexpected costs and unknown risks and liabilities associated with 
 strategic investments or acquisitions.                             |

Even if the transaction is consummated, NewGenIvf may only have limited control over